236 related articles for article (PubMed ID: 35037466)
1. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
[TBL] [Abstract][Full Text] [Related]
2. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
3. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression.
Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM
J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180
[TBL] [Abstract][Full Text] [Related]
5. Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.
Menezes LF; Lin CC; Zhou F; Germino GG
EBioMedicine; 2016 Mar; 5():183-92. PubMed ID: 27077126
[TBL] [Abstract][Full Text] [Related]
6. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.
Wang X; Jiang L; Thao K; Sussman CR; LaBranche T; Palmer M; Harris PC; McKnight GS; Hoeflich KP; Schalm S; Torres VE
J Am Soc Nephrol; 2022 Jun; 33(6):1087-1104. PubMed ID: 35236775
[TBL] [Abstract][Full Text] [Related]
7. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
8. Cux1 promotes cell proliferation and polycystic kidney disease progression in an ADPKD mouse model.
Porath B; Livingston S; Andres EL; Petrie AM; Wright JC; Woo AE; Carlton CG; Baybutt R; Vanden Heuvel GB
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F1050-F1059. PubMed ID: 28701314
[TBL] [Abstract][Full Text] [Related]
9. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1
Arroyo J; Escobar-Zarate D; Wells HH; Constans MM; Thao K; Smith JM; Sieben CJ; Martell MR; Kline TL; Irazabal MV; Torres VE; Hopp K; Harris PC
Kidney Int; 2021 Jun; 99(6):1392-1407. PubMed ID: 33705824
[TBL] [Abstract][Full Text] [Related]
10. CD8
Kleczko EK; Marsh KH; Tyler LC; Furgeson SB; Bullock BL; Altmann CJ; Miyazaki M; Gitomer BY; Harris PC; Weiser-Evans MCM; Chonchol MB; Clambey ET; Nemenoff RA; Hopp K
Kidney Int; 2018 Dec; 94(6):1127-1140. PubMed ID: 30249452
[TBL] [Abstract][Full Text] [Related]
11. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression.
Nguyen DT; Kleczko EK; Dwivedi N; Monaghan MT; Gitomer BY; Chonchol MB; Clambey ET; Nemenoff RA; Klawitter J; Hopp K
JCI Insight; 2023 Jan; 8(1):. PubMed ID: 36422996
[TBL] [Abstract][Full Text] [Related]
12. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
[TBL] [Abstract][Full Text] [Related]
13. Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.
Leonhard WN; Zandbergen M; Veraar K; van den Berg S; van der Weerd L; Breuning M; de Heer E; Peters DJ
J Am Soc Nephrol; 2015 Jun; 26(6):1322-33. PubMed ID: 25361818
[TBL] [Abstract][Full Text] [Related]
14. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.
Trott JF; Hwang VJ; Ishimaru T; Chmiel KJ; Zhou JX; Shim K; Stewart BJ; Mahjoub MR; Jen KY; Barupal DK; Li X; Weiss RH
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1855-F1868. PubMed ID: 30280600
[TBL] [Abstract][Full Text] [Related]
15. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.
Hopp K; Ward CJ; Hommerding CJ; Nasr SH; Tuan HF; Gainullin VG; Rossetti S; Torres VE; Harris PC
J Clin Invest; 2012 Nov; 122(11):4257-73. PubMed ID: 23064367
[TBL] [Abstract][Full Text] [Related]
16. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.
Chaudhary A; He Z; Atwood DJ; Miyazaki M; Oto OA; Davidoff A; Edelstein CL
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1004-F1015. PubMed ID: 38634129
[TBL] [Abstract][Full Text] [Related]
17. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
18. Pkd1-targeted mutation reveals a role for the Wolffian duct in autosomal dominant polycystic kidney disease.
Tee JB; Dnyanmote AV; Lorenzo MK; Lee OR; Grisaru S; Suk M; Acott PD
J Dev Orig Health Dis; 2020 Feb; 11(1):78-85. PubMed ID: 31412963
[TBL] [Abstract][Full Text] [Related]
19. Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease.
Saravanabavan S; Rangan GK
Nephrology (Carlton); 2021 Nov; 26(11):920-930. PubMed ID: 34331378
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of polycystic kidney disease expression profiles defines strong involvement of injury repair processes.
Malas TB; Formica C; Leonhard WN; Rao P; Granchi Z; Roos M; Peters DJ; 't Hoen PA
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F806-F817. PubMed ID: 28148532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
